Figure 2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Year: 2024
Type: other
Abstract: Genomic features and clinico-demographic associations of cohort. A, Total number of tumors positive for each mutated gene. B, Percentage of total tumors from each study site for the top 20 most commonly mutated genes. C, Prevalence of co-mutations among APC, EGFR, STK11, TP53, and KRAS. Red indicates strong co-mutation whereas blue indicates mutual exclusivity. D, Percentage of indicated tumor types with mutations in APC, EGFR, STK11, TP53, and KRAS. E, Age of patients among (−) and (+) gene mutation cohorts. The red line indicates the median age. F, Ratio of males to females in (−) and (+) gene mutation cohorts. G, Percentage of total (−) and (+) cohorts composed by indicated racial groups. *, P < 0.05; **, P < 0.01; #, P < 0.001; ns, not significant.
Authors: Elisabeth Heath, Gregory Dyson, Jennifer R. Ribeiro, Joanne Xiu, Kelsey Poorman, Hirva Mamdani, Mohammed N. Al-Hallak, Anthony F. Shields, Jailan A. Elayoubi, Ira S. Winer, Frank C. Cackowski, Gary A. Puckrein, Gilberto de Lima Lopes, Nathaniel Jones, Ralph J. Hauke, Samuel A. Kareff, Milan Radovich, George W. Sledge, David B. Spetzler, Gregory A. Vidal, John L. Marshall
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4403136236